Creative Medical Technology Holdings, Inc. (CELZ) Reports 93% Response, ~65% Pain Drop in OA Pilot

Creative Medical Technology Holdings (CELZ) reported a 93% response rate in a 30-patient study of Ultrasome for knee osteoarthritis, with participants showing significant pain reduction and improved quality of life. The study, presented at a conference, had no serious adverse events. The company plans to publish detailed findings and seeks further development. Ultrasome is not FDA-approved.

Creative Medical Technology Holdings (CELZ) presented clinical and lab findings for Ultrasome™, its cell-free regenerative medicine platform. A 30-patient study showed 65% reduction in average pain score and 52% reduction in WOMAC score over six months. No serious adverse events were reported. The company plans to publish full findings in a peer-reviewed manuscript.

Creative Medical Technology Holdings (NASDAQ: CELZ) issued a mid-year update. It said Olastrocel (CELZ-201) has WHO-approved naming and reported positive interim 180-day ADAPT trial results; the FDA cleared an expanded cohort for patients using <90 mg/day morphine equivalents. Ultrasome™ pilot data showed a 93% primary endpoint response. The CELZ-Biodefense Atlas program advanced to nationwide AI-enabled veteran data collection.

Creative Medical Technology Holdings (CELZ) said it secured about $4.5M in gross proceeds via warrant exercises and related stock purchases. The company will exercise warrants for up to 2,790,340 shares and investors will buy 5,580,680 shares at $1.60/share, with new five-year warrants issued. Closing is expected June 30, 2026.

Creative Medical Technology (CELZ) said the FDA cleared an amended protocol to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain. The company will add 15 patients using <90 mg morphine equivalents/day; the new cohort is 85% enrolled and uses its AI pain-medication monitoring. Creative Medical cited positive 180-day interim results and a DSMB report of no significant adverse events, and said it is preparing for Phase 3 discussions.

AMD stock trades at 18.3x sales, with growth expected from its data center business. The company began shipping new data center chips, driving record $8.5B revenue in Q3, up 97% YoY. Management targets data center to be 80% of revenue by 2027, with total revenue expected to grow over 80%. AMD stock is 21.7% below its October high, despite a 114% return over the past year.